< Tillbaka till sökresultaten

Jeltsch Michael

Beskrivning

Finnish-German biochemist, high school diploma from Gymnasium An der Stenner (Iserlohn, Germany), undergraduate studies at the University of Hamburg, PhD from the University of Helsinki, Finland in 2003 with Kari Alitalo: discovery of the first growth factors for lymphatic vessels: VEGF-C and VEGF-D. Since 2020 associate professor at the Faculty of Pharmacy, University of Helsinki. Experience in three biotech startups with several patents and three drugs in clinical trials: OPT-302/sozinibercept (developer, phase III), VGX-100 and Lymfactin (co-developer, up to phase I and II, respectively). Currently working on novel and sustainable protein expression systems.

Affiliering

Helsingfors universitet
Associate Professor in Pharmaceutical Protein Drug Research
Drug Research Program
2020 - nuvarande
Källa: ORCID
University of Helsinki
Group leader
Translational Cancer Biology Program/Individual Drug Therapy Research Program
2013 - 2020
Källa: ORCID
Wihuri Research Institute
Postdoctoral Fellow
2013
Källa: ORCID
University of Helsinki
Postdoctoral Fellow
Molecular/Cancer Biology Laboratory
2003 - 2013
Källa: ORCID
Vegenics Ltd/Circadian Technologies via Licentia Oy (now Opthea)
Contract Researcher
2007 - 2011
Källa: ORCID
Lymphatix Oy (acquired by Ark Therapeutics)
Researcher
2006 - 2007
Källa: ORCID
Helsinki University Licencing Ltd./Licentia Ltd.
Contract Researcher
1999 - 2005
Källa: ORCID
University of Helsinki
Graduate Student
Molecular/Cancer Biology Laboratory
1996 - 2002
Källa: ORCID
Heinrich-Pette-Institut Leibniz-Institut fur Experimentelle Virologie
Research Assistant
Group Hans Will
1994 - 1995
Källa: ORCID

Utbildning (4)

PhD
University of Helsinki
MSc
University of Helsinki
BSc/"Vordiplom"
University of Hamburg
Baccalaureate
Gymnasium An der Stenner

Publikationer (55)

2023
The Relationship between the Secondary Vascular System and the Lymphatic Vascular System in Fish
DOI
10.20944/preprints202312.2119.v1
2022
Expansion and collapse of VEGF diversity in major clades of the animal kingdom
DOI
10.1101/2022.09.19.507521
Lymphatic-to-blood vessel transdifferentiation in zebrafish
DOI
10.1038/s44161-022-00073-1

Beviljade finansiering (1)

Development of a biotherapeutical to counter cancer “resistance” to presently used anti- angiogenic drugs
Finlands Akademi
2013 - 2018

Aktiviteter och priser (9)

Konferenspresentation
Drug-induced lymphangiogenesis
2022
International collaboration: Nej
Annan aktivitet
The Proteolytic Activation of Vascular Endothelial Growth Factors
2021
International collaboration: Nej
Recensent av en vetenskaplig tidskrift
Reviewer
SpringerNature
2021
International collaboration: Nej